| |
COMPOSITION
Each Mafepain tablet contains 500mg mefenamic
acid B.P. Action: Mafepain, mefenamic acid is a non-steroidal anti-inflammatory
agent with analgesic and antipyretic effect. It has been shown to
inhibit prostaglandin activity. |
| |
INDICATIONS
– Mafepain is indicated for relief of mild to
moderate pain including pain of muscular or traumatic origin, dental
pain & headache.
– Menstrual disorders (e.g. menstrual pain)
– Joint inflammations.
– Pain or inflammation following injury or surgery. |
| |
CONTRA-INDICATIONS
Mafepain (Mefenamic acid) is contra-indicated
in:
– Patients with hypersensitivity to mefenamic acid.
– Patients in whom aspirin or other non-steroidal anti- inflammatory
drugs precipitate symptoms of bronchos- pasm, allergic rhinitis or
urticaria.
– Patients suffering from inflammatory bowel disease, peptic and/or
intestinal ulceration.
– Patients with renal or hepatic impairment. |
| |
PRECAUTIONS
– Safety in pregnancy has not been established.
– Caution should be exercised in patients suffering from dehydration
and renal diseases, particularly the elderly.
– Concurrent therapy with other drugs which have a high affinity for
plasma proteins may necessitate a modification in dosage.
– In the case of anticoagulants the dose of the anticoagulant may
need to be reduced.
– In dysmenorrhoea and menorrhagia, lack of response should alert
the physician to investigate other causes. |
| |
WARNINGS
AND ADVERSE
EFFECTS
– Diarrhoea occasionally occurs following
the use of mefenamic acid. Although this may occur soon after starting
of treatment, it may also occur after several months of continuous
use. The diarrhoea has been investigated in some patients who have
continued this drug in spite of its continued presence; these patients
were found to have associated proctocolitis.
– If diarrhoea does develop; the drug should be discontinued immediately
and the patient should not receive mefenamic acid again.
– Skin rashes have been observed following the administration of
mefenamic acid and the occurrence of a rash is a definite indication
to stop medication.
– As with other prostaglandin inhibitors, allergic glomerulonephritis
has occurred occasionally.
– Rarely, thrombocytopenia has been reported with mefenamic acid.
In some cases reversible haemolytic anaemia has occurred with continuous
administration of mefenamic acid for 12 months or longer.
– Temporary lowering of the white blood cells count has been reported.
Blood studies should therefore be carried out during long term administration.
– Bronchospasm may be precipitated in patients suffering from, or
with a previous history of bronchial asthma or allergic disease.
– Patients on prolonged therapy should also be kept under surveillance
with particular attention to liver dysfunction; should this appear,
it is an indication to discontinue therapy.
– Drowsiness and dizziness have rarely been reported.
|
| |
DOSAGE AND ADMINISTRATION
Adults and children over 12 years of age:
– 1 tablet (500 mg) three times daily.
– In menorrhagia, to be administered on the first day of excessive
bleeding and continued according to the physician's advice.
– In dysmenorrhoea, to be administered at the onset of menstrual pain
and continued according to the physician's advice.
Childrens:
– It is recommended that children under 12 years of age should not
be given mefenamic acid 500mg tablets |
| |
PRESENTATIONS
Mafepain is available as 500 mg tablets. |
